| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00415-009-5240-1 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1007/s00415-009-5240-1 |
| P698 | PubMed publication ID | 19711119 |
| P5875 | ResearchGate publication ID | 51438033 |
| P2093 | author name string | Mark Stacy | |
| Ariane Park | |||
| P2860 | cites work | Staging of brain pathology related to sporadic Parkinson's disease | Q28131702 |
| Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension | Q28346311 | ||
| Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine | Q33173729 | ||
| Neurophysiologic study of central pain in patients with Parkinson disease | Q33308473 | ||
| Managing late complications of Parkinson's disease | Q33545302 | ||
| Rivastigmine for dementia associated with Parkinson's disease | Q33983707 | ||
| Sleep disorders in Parkinson's disease: epidemiology and management | Q34155397 | ||
| Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system | Q34395267 | ||
| Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study | Q34637078 | ||
| Memantine agonist action at dopamine D2High receptors | Q34713522 | ||
| Depression and Parkinson's disease: a review | Q35313173 | ||
| Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease | Q79169769 | ||
| ??? | Q64768957 | ||
| ??? | Q64865570 | ||
| Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study | Q35467921 | ||
| Olfactory function distinguishes vascular parkinsonism from Parkinson's disease | Q35478221 | ||
| Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study | Q35488511 | ||
| Integrative control of the lower urinary tract: preclinical perspective | Q35545750 | ||
| Management of overactive bladder | Q35671074 | ||
| Recent developments in the management of overactive bladder: focus on the efficacy and tolerability of once daily solifenacin succinate 5 mg. | Q36120325 | ||
| The overactive bladder: review of current pharmacotherapy in adults. Part 2: treatment options in cases refractory to anticholinergics | Q36428476 | ||
| Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology | Q36445098 | ||
| The discovery of the pressor effect of DOPS and its blunting by decarboxylase inhibitors | Q36611622 | ||
| Treating dopamimetic psychosis in Parkinson's disease: structured review and meta-analysis | Q36637123 | ||
| Psychosis in Parkinson's disease: phenomenology, frequency, risk factors, and current understanding of pathophysiologic mechanisms. | Q37103581 | ||
| Neural control of the gastrointestinal tract: implications for Parkinson disease | Q37149364 | ||
| Insights into REM sleep behavior disorder pathophysiology in brainstem-predominant Lewy body disease | Q37241989 | ||
| Sodium oxybate for excessive daytime sleepiness in Parkinson disease: an open-label polysomnographic study | Q38386657 | ||
| Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group | Q39456400 | ||
| Nighttime sleep problems and daytime sleepiness in Parkinson's disease | Q40160509 | ||
| Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease | Q40632672 | ||
| Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease. | Q42512004 | ||
| Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations | Q42544779 | ||
| Management of constipation in the elderly: emerging therapeutic strategies | Q42555451 | ||
| SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study. | Q42655854 | ||
| Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease | Q44351576 | ||
| Longitudinal outcome of Parkinson's disease patients with psychosis | Q44471614 | ||
| Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. | Q44723768 | ||
| Motor changes during sertraline treatment in depressed patients with Parkinson's disease*. | Q46475659 | ||
| Striatal dopamine level increases in the urinary storage phase in cats: an in vivo microdialysis study. | Q46659988 | ||
| Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study | Q46756287 | ||
| Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease | Q46761473 | ||
| Benefits of rivastigmine on attention in dementia associated with Parkinson disease | Q46814969 | ||
| Effect of tegaserod on gut transit in male and female subjects | Q46841569 | ||
| Quetiapine for agitation or psychosis in patients with dementia and parkinsonism | Q47576720 | ||
| Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study | Q48115841 | ||
| Chronic pain in Parkinson's disease: the cross-sectional French DoPaMiP survey. | Q48432660 | ||
| Update on the pharmacology of REM sleep behavior disorder. | Q48490636 | ||
| Cognitive deficits in the early stages of Parkinson's disease. | Q48800336 | ||
| Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations. | Q48859260 | ||
| Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. | Q49153394 | ||
| Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration. | Q51911689 | ||
| Risk of dementia in Parkinson's disease: a community-based, prospective study. | Q51968295 | ||
| Visual dysfunction in Parkinson disease without dementia. | Q51987311 | ||
| Macrogol 3350/electrolyte improves constipation in Parkinson's disease and multiple system atrophy. | Q53881612 | ||
| Treatment with antiparkinson and antidepressant drugs: A register-based, pharmaco-epidemiological study | Q60643553 | ||
| Shoulder pain: a presenting symptom of Parkinson disease | Q64969623 | ||
| Progressive worsening of spatial and chromatic processing deficits in Parkinson disease | Q74581652 | ||
| P921 | main subject | Parkinson's disease | Q11085 |
| P304 | page(s) | 293-298 | |
| P577 | publication date | 2009-08-01 | |
| P1433 | published in | Journal of Neurology | Q6295649 |
| P1476 | title | Non-motor symptoms in Parkinson's disease. | |
| P478 | volume | 256 Suppl 3 |
| Q26744733 | A Review of Sleep and Its Disorders in Patients with Parkinson's Disease in Relation to Various Brain Structures |
| Q28116203 | ATP13A2 and Alpha-synuclein: a Metal Taste in Autophagy |
| Q34784683 | Abnormal pulmonary function and respiratory muscle strength findings in Chinese patients with Parkinson's disease and multiple system atrophy--comparison with normal elderly |
| Q30436300 | Alterations of eye movement control in neurodegenerative movement disorders |
| Q37789524 | Are synucleinopathies prion-like disorders? |
| Q43614386 | Assessment of nasal parameters in determination of olfactory dysfunction in Parkinson's disease |
| Q47137783 | Biological and Clinical Implications of Comorbidities in Parkinson's Disease |
| Q42592654 | Bright light therapy in Parkinson's disease: an overview of the background and evidence |
| Q28384426 | Circadian dysfunction may be a key component of the non-motor symptoms of Parkinson's disease: insights from a transgenic mouse model |
| Q57072461 | Clinical Heterogeneity Among Variants in Parkinson's Disease: A Meta-Analysis |
| Q48787541 | Clinical validation of Movement Disorder Society-recommended diagnostic criteria for Parkinson's disease with dementia. |
| Q33693692 | Comparison of peripapillary choroidal thickness between healthy subjects and patients with Parkinson's disease. |
| Q48549458 | Concordance between severity of disease, prevalence of nonmotor symptoms, patient-reported quality of life and disability and use of medication in Parkinson's disease. |
| Q42121012 | Contribution of insula in Parkinson's disease: A quantitative meta-analysis study |
| Q48212516 | Correlations among multifocal electroretinography and optical coherence tomography findings in patients with Parkinson's disease |
| Q48091966 | Correlations between plasma levels of amino acids and nonmotor symptoms in Parkinson's disease |
| Q33593735 | Cortical and Striatal Reward Processing in Parkinson's Disease Psychosis |
| Q36120727 | Diabetes care among elderly medicare beneficiaries with Parkinson's disease and diabetes |
| Q33593384 | Dopamine, reward, and frontostriatal circuitry in impulse control disorders in Parkinson's disease: insights from functional imaging |
| Q27301058 | Early Parkinson's disease symptoms in α-synuclein transgenic monkeys |
| Q92219480 | Effects of Combined Treatment with Acupuncture and Chunggan Formula in a Mouse Model of Parkinson's Disease |
| Q21131738 | Effects of Resistance Training on Measures of Muscular Strength in People with Parkinson's Disease: A Systematic Review and Meta-Analysis |
| Q33577182 | Effects of a combination treatment of KD5040 and L-dopa in a mouse model of Parkinson's disease |
| Q30475554 | Effects of subthalamic nucleus stimulation on emotional prosody comprehension in Parkinson's disease |
| Q58090329 | Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic Parkinson's disease |
| Q41884810 | Evaluating rehabilitation interventions in Parkinson's disease with functional MRI: a promising neuroprotective strategy |
| Q48399270 | Exendin-4 reverses biochemical and behavioral deficits in a pre-motor rodent model of Parkinson's disease with combined noradrenergic and serotonergic lesions. |
| Q37516494 | Gastrointestinal Dysfunctions in Parkinson's Disease: Symptoms and Treatments |
| Q37801855 | Gene therapy: a viable therapeutic strategy for Parkinson's disease? |
| Q38823617 | Glaucoma correlates with increased risk of Parkinson's disease in the elderly: a national-based cohort study in Taiwan |
| Q50250125 | Impact of cognitive dysfunction on drooling in Parkinson's disease. |
| Q48357356 | Improved cognition while cycling in Parkinson's disease patients and healthy adults. |
| Q90047541 | In Vitro, In Silico, and In Vivo Assessments of Pharmacokinetic Properties of ZM241385 |
| Q57488748 | Levodopa-induced respiratory dysfunction confirmed by levodopa challenge test: A case report |
| Q48259976 | Link between non-motor symptoms and cognitive dysfunctions in de novo, drug-naive PD patients |
| Q27016128 | Lower limb progressive resistance training improves leg strength but not gait speed or balance in Parkinson's disease: a systematic review and meta-analysis |
| Q38233285 | Management of anxiety and motor symptoms in Parkinson's disease |
| Q38800103 | Management of lower urinary tract symptoms in Parkinson's disease in the neurology clinic |
| Q41863327 | Measuring hemoglobin levels in the optic disc of Parkinson's disease patients using new colorimetric analysis software. |
| Q37016546 | Mechanisms of orthostatic hypotension and supine hypertension in Parkinson disease |
| Q48785960 | Mismatch negativity-like potential (MMN-like) in the subthalamic nuclei in Parkinson's disease patients. |
| Q34038937 | Mitochondrial oxidant stress in locus coeruleus is regulated by activity and nitric oxide synthase |
| Q37790044 | Multi-organ autonomic dysfunction in Parkinson disease |
| Q39322909 | Multiparametric brainstem segmentation using a modified multivariate mixture of Gaussians |
| Q30611520 | Neuroimaging of brain changes associated with cognitive impairment in Parkinson's disease |
| Q34306196 | Neurologists' diagnostic accuracy of depression and cognitive problems in patients with parkinsonism |
| Q94595252 | Objective measurement in Parkinson's disease: a descriptive analysis of Parkinson's symptom scores from a large population of patients across the world using the Personal KinetiGraph® |
| Q34522336 | On the analysis of EEG power, frequency and asymmetry in Parkinson's disease during emotion processing |
| Q33636232 | Orthostatic and supine blood pressures are associated with white matter hyperintensities in Parkinson disease |
| Q80319319 | Parkinson disease: an update |
| Q36503306 | Parkinson's disease related pain: a review of recent findings |
| Q43721437 | Prevalence of headache in patients with Parkinson's disease and its association with the side of motor symptom onset. |
| Q48640356 | Prevalence of non-motor symptoms in young-onset versus late-onset Parkinson's disease. |
| Q38424277 | Psychometric validation of the revised SCOPA-Diary Card: expanding the measurement of non-motor symptoms in Parkinson's disease |
| Q47642094 | Retinal and Choroidal Changes in Patients with Parkinson's Disease Detected by Swept-Source Optical Coherence Tomography. |
| Q38543130 | Sensory abnormalities and pain in Parkinson disease and its modulation by treatment of motor symptoms |
| Q45022135 | Summaries of plenary, symposia, and oral sessions at the XXII World Congress of Psychiatric Genetics, Copenhagen, Denmark, 12-16 October 2014. |
| Q91774191 | Systematic review of genetic variants associated with cognitive impairment and depressive symptoms in Parkinson's disease |
| Q38173777 | Systematic review of the effectiveness of occupational therapy-related interventions for people with Parkinson's disease |
| Q64266630 | T-Cell-Driven Inflammation as a Mediator of the Gut-Brain Axis Involved in Parkinson's Disease |
| Q64969685 | Taurine protects noradrenergic locus coeruleus neurons in a mouse Parkinson's disease model by inhibiting microglial M1 polarization |
| Q41276024 | The Effects of Group-Based versus Individual-Based Tai Chi Training on Nonmotor Symptoms in Patients with Mild to Moderate Parkinson's Disease: A Randomized Controlled Pilot Trial. |
| Q35833984 | The Interplay between Alpha-Synuclein Clearance and Spreading |
| Q93164939 | The Noradrenergic System in Parkinson's Disease |
| Q30428109 | The Ronnie Gardiner Rhythm and Music Method - a feasibility study in Parkinson's disease |
| Q36494212 | The Therapeutic Potential of Exercise to Improve Mood, Cognition, and Sleep in Parkinson's Disease |
| Q44340598 | The fine structure of the dopaminergic innervation of area 10 of macaque prefrontal cortex |
| Q38105645 | The hallmarks of Parkinson's disease |
| Q34925276 | The heterogeneity of early Parkinson's disease: a cluster analysis on newly diagnosed untreated patients |
| Q48301186 | The impact of sleep and mood disorders on quality of life in Parkinson's disease patients |
| Q41843365 | Traditional chinese medicine improves activities of daily living in Parkinson's disease |
| Q39332126 | Translation of WNT developmental programs into stem cell replacement strategies for the treatment of Parkinson's disease |
| Q38204871 | Uncovering the role of the insula in non-motor symptoms of Parkinson's disease |
| Q36764796 | Use of Fourier-domain OCT to detect retinal nerve fiber layer degeneration in Parkinson's disease patients |
Search more.